Compare NUTX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUTX | ARVN |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | 944 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.4M | 781.0M |
| IPO Year | 2009 | 2018 |
| Metric | NUTX | ARVN |
|---|---|---|
| Price | $94.33 | $11.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 20 |
| Target Price | ★ $252.50 | $15.35 |
| AVG Volume (30 Days) | 163.2K | ★ 770.9K |
| Earning Date | 03-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.93 | ★ 58.84 |
| EPS | ★ 10.48 | N/A |
| Revenue | ★ $875,257,000.00 | $262,600,000.00 |
| Revenue This Year | $8.28 | N/A |
| Revenue Next Year | $1.96 | N/A |
| P/E Ratio | $9.01 | ★ N/A |
| Revenue Growth | ★ 82.36 | N/A |
| 52 Week Low | $45.88 | $5.90 |
| 52 Week High | $193.07 | $14.22 |
| Indicator | NUTX | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 40.03 | 33.97 |
| Support Level | $81.70 | $11.07 |
| Resistance Level | $110.29 | $14.03 |
| Average True Range (ATR) | 6.97 | 0.67 |
| MACD | 1.07 | -0.28 |
| Stochastic Oscillator | 29.55 | 10.66 |
Nutex Health Inc is a physician-led, healthcare services and operations company with various hospital facilities in the U.S. states (hospital division), and a primary care-centric, risk-bearing population health management division. The company has three segments: the hospital division, the PHM division, and the real estate division. The hospital division implements and operates health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management (PHM) division owns and operates provider networks such as independent physician associations (IPAs). The Real Estate Entities own the land and hospital buildings which are leased to its hospital entities. The majority of the revenue is derived from the Hospital division.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.